| Business Summary | | DUSA
Pharmaceuticals,
Inc.
is
a
pharmaceutical
company
developing
drugs
in
combination
with
light
devices
to
treat
or
detect
a
variety
of
conditions
in
processes
known
as
photodynamic
therapy
or
photodetection.
The
Company
is
engaged
primarily
in
the
research
and
development
of
its
first
drug,
Levulan
brand
of
aminolevulinic
acid
HCl
(ALA)
with
light,
for
use
in
a
broad
range
of
medical
conditions.
Levulan
Kerastick
20%
Topical
Solution
with
PDT
uses
the
Company's
first
light
device
product,
called
the
BLU-U,
for
the
treatment
of
actinic
keratoses
(AKs)
of
the
face
or
scalp.
AKs
are
precancerous
skin
lesions
caused
by
chronic
sun
exposure. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | DUSA
Pharmaceuticals
Inc.
is
a
development
stage
pharmaceutical
company
engaged
in
the
development
of
photodynamic
therapy
and
photodiagnosis
utilizing
5-aminolevulinic
acid
for
various
medical
indications.
For
the
six
months
ended
6/30/01,
revenues
totaled
$2.7
million,
up
from
$603
thousand.
Net
loss
rose
5%
to
$2.8
million.
Revenues
reflect
the
launch
of
products
and
research
grants.
Higher
loss
reflects
increased
R&D
expenses
due
to
higher
personnel
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| D. Geoffrey Shulman, M.D., 46 Chairman,
Pres, CEO | $484K | -- | John Mattern, 52 CFO,
VP-Fin. | -- | -- | Ronald Carroll, 52 Exec.
VP, COO | 289K | $597K | Stuart Marcus, M.D., Ph.D., 54 Sr.
VP of Scientific Affairs and CSO | 299K | -- | Mark Carota, 45 VP-Operations | 175K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|